Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease?

Movement Disorders

Volumn 23, Issue 12, 2008, Pages 1689-1695

  Lim, Shen Yang ^a   Farrell, Michael J ^b   Gibson, Stephen J ^c   Helme, Robert D ^d   Lang, Anthony E ^e   Evans, Andrew H ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

^d WESTERN HOSPITAL   (Australia)

^e TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Central pain; Dyskinesia; Parkinson's disease; Parkinsonian pain; Sensitization

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLD TOLERANCE; CONTROLLED STUDY; DISEASE COURSE; DRUG RESPONSE; DYSKINESIA; FEMALE; HUMAN; MALE; MORNING DOSAGE; NOCICEPTION; OUTCOME ASSESSMENT; PAIN; PAIN ASSESSMENT; PAIN THRESHOLD; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE DRUG DOSE; WATER IMMERSION;

AGED; ANTIPARKINSON AGENTS; DYSKINESIAS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; PARKINSONIAN DISORDERS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 57049113204     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22111     Document Type: Article

References (34)

1. Goetz CG, Tanner CM, Levy M, Wilson RS, Garron DC. Pain in Parkinson's disease. Mov Disord 1986;1:45-49.
2. Tinazzi M, Del Vesco C, Fincati E, et al. Pain and motor complications in Parkinson's disease. J Neurol Neurosurg Psychiatry 2006;77:822-825.
3. Snider SR, Fahn S, Isgreen WP, et al. Primary sensory symptoms in parkinsonism. Neurology 1976;26:423-429.
4. Nutt JG, Carter JH. Sensory symptoms in parkinsonism related to central dopaminergic function. Lancet 1984;324:456-457.
5. Quinn NP, Koller WC, Lang AE, Marsden CD. Painful Parkinson's disease. Lancet 1986;1:1366-1369.
6. Vela L, Facca A, Lyons KE, Lieberman AN. Pain and Parkinson's disease. Mov Disord 2002;17 (Suppl5):S154-155.
7. Rascol O, Negre-Pages L, DoPaMiP Study Group. Chronic pain in Parkinson's disease: the DoPaMiP study. Mov Disord. 2006; 21(Suppl 15):S490.
8. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987;2:73-91.
9. Djaldetti R, Shifrin A, Rogowski Z, Sprecher E, Melamed E, Yarnitsky D. Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology 2004;62:2171-2175.
10. Vela L, Baron M, Barriga FJ, et al. Levodopa does not raise pain-pressure threshold in Parkinson disease. Mov Disord. 2006; 21(Suppl 15):S496.
11. Brefel-Courbon C, Payoux P, Thalamas C, et al. Effect of Levodopa on Pain Threshold in Parkinson's Disease: a Clinical and Positron Emission Tomography Study. Mov Disord 2005;20: 1557-1563.
12. Slaoui T, Gerdelat-Mas A, Ory-Magne F, Rascol O, Brefel-Courbon C. Levodopa changes pain thresholds in Parkinson disease (PD) patients. Mov Disord 2006;21(Suppl 15):S503.
13. Schestatsky P, Kumru H, Valls-Solé J, et al. Neurophysiologic study of central pain in patients with Parkinson disease. Neurology 2007;69:2162-2169.
14. Gracely RH, Geisser ME, Giesecke T, et al. Pain catastrophizing and neural responses to pain among persons with fibromyalgia. Brain 2004;127:835-843.
15. Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 2005;20:151-157.
16. Stacy M, Bowron A, Guttman M, et al. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 2005;20:726-733.
17. Evans AH, Katzenschlager R, Paviour D, et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 2004;19:397-405.
18. Nutt JG, Carter JH, Lea ES, Sexton GJ. Evolution of the Response to Levodopa during the First 4 Years of Therapy. Ann Neurol 2002;51:686-693.
19. Clissold BG, McColl CD, Reardon KR, Shiff M, Kempster PA. Longitudinal study of the motor response to levodopa in Parkinson's disease. Mov Disord 2006;21:2116-2121.
20. Zappia M, Oliveri RL, Bosco D, et al. The long-duration response to L-dopa in the treatment of early PD. Neurology 2000;54:1910-1915.
21. Chudler EH, Dong WK. The role of the basal ganglia in nociception and pain. Pain 1995;60:3-38.
22. Altier N, Stewart J. The role of dopamine in the nucleus accumbens in analgesia. Life Sci 1999;65:2269-2287.
23. Gear RW, Aley KO, Levine JD. Pain-induced analgesia mediated by mesolimbic reward circuits. J Neurosci 1999;19:7175-7181.
24. Uhl GR, Hedreen JC, Price DL. Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology 1985;35:1215-1218.
25. German DC, Manaye K, Smith WK, Woodward DJ, Saper CB. Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann Neurol 1989;26:507-514.
26. Nutt JG. Continuous dopaminergic stimulation: is it the answer to the motor complications of levodopa? Mov Disord 2007;22:1-9.
27. Moro E, Esselink RJA, Benabid AL, Pollak P. Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation. Brain 2002;125:2408-2417.
28. Guigoni C, Li Q, Aubert I, et al. Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia. J Neurosci 2005;25:2102-2107.
29. Schultz W. Dopamine neurons and their role in reward mechanisms. Curr Opin Neurobiol 1997;7:191-197.
30. Evans AH, Pavese N, Lawrence AD, et al. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006;59:852-858.
31. Jiang W, Chapman CE, Lamarre Y. Modulation of somatosensory evoked responses in the primary somatosensory cortex produced by intracortical microstimulation of the motor cortex in the monkey. Exp Brain Res 1990;80:333-344.
32. Garcia-Larrea L, Peyron R. Motor cortex stimulation for neuropathic pain: from phenomenology to mechanisms. NeuroImage 2007;37(Suppl 1):S71-79.
33. Rascol O, Sabatini U, Brefel C, et al. Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia. Brain 1998;121:527-533.
34. Marras C, Lang AE. Measuring motor complications in clinical trials for early Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:143-146.